Neuphoria Therapeutics Inc. Sends Letter to Stockholders
Neuphoria Therapeutics Inc. (NEUP)
Company Research
Source: GlobeNewswire
Files Definitive Proxy Statement for 2025 Annual Meeting of Stockholders Urges Stockholders to Vote “FOR” BOTH Neuphoria Therapeutics Nominees on WHITE Proxy Card BURLINGTON, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”), a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders, today issued a letter to its stockholders regarding Neuphoria’s 2025 Annual Meeting of Stockholders (“2025 Annual Meeting”), which is scheduled to be held on December 12, 2025. At the 2025 Annual Meeting, Neuphoria stockholders will have the opportunity to protect their investment in the Company by voting FOR the Company’s two highly qualified nominees: Peter Miles Davies and David Wilson. These directors bring deep investment, transactional, and capital allocation expertise directly relevant to the Company’s ongoing review of strategic alternatives. Ne
Show less
Read more
Impact Snapshot
Event Time:
NEUP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NEUP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NEUP alerts
High impacting Neuphoria Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
NEUP
News
- Neuphoria Therapeutics (NASDAQ:NEUP) had its price target lowered by analysts at HC Wainwright from $21.00 to $7.00. They now have a "buy" rating on the stock.MarketBeat
- Neuphoria Responds to Lynx1’s Revised Indication of Interest at a Reduced Price and PremiumGlobeNewswire
- Lynx1 Sends Open Letter to Fellow Neuphoria Shareholders [Yahoo! Finance]Yahoo! Finance
- Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions [Yahoo! Finance]Yahoo! Finance
- Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 FictionsGlobeNewswire